Literature DB >> 12659691

Differential uptake of (18)F-fluorodeoxyglucose by experimental tumors xenografted into immunocompetent and immunodeficient mice and the effect of immunomodification.

Marcelo Mamede1, Tsuneo Saga, Takayoshi Ishimori, Yuji Nakamoto, Noriko Sato, Tatsuya Higashi, Takahiro Mukai, Hisataka Kobayashi, Junji Konishi.   

Abstract

PURPOSE: To study the contribution of immunologic background to the uptake of fluorine-18-fluorodeoxyglucose ((18)F-FDG) by the tumor tissues.
METHODS: The uptakes of (18)F-FDG to the same experimental tumor model (SCCVII) xenografted into immunocompetent and immunodeficient (athymic) mice were compared. In addition, the immunomodifying effect of steroid on the uptake of (18)F-FDG by these tumors was investigated.
RESULTS: The uptake of (18)F-FDG by the tumors in immunocompetent mice was significantly higher than that in immunodeficient (athymic) mice. Although steroid pretreatment had no effect on the tumor uptake in immunodeficient mice, it significantly decreased the tumor uptake in immunocompetent mice.
CONCLUSION: The higher tumor uptake of (18)F-FDG observed in immunocompetent mice, modulated by steroid pretreatment, was contributed by the host immune reaction, probably cellular immunity employed by T-lymphocytes. These findings can clinically conclude that the intense accumulation of (18)F-FDG in the metastatic lymph nodes, which contain only a small number of cancer cells, was caused by the enhanced uptake of (18)F-FDG by activated T-lymphocytes due to host immunity against cancer cells present in metastatic lymph nodes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12659691      PMCID: PMC1502404          DOI: 10.1016/s1476-5586(03)80010-6

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  23 in total

1.  Performance assessment of O-18 water purifier.

Authors:  H Kitano; Y Magata; A Tanaka; T Mukai; Y Kuge; K Nagatsu; J Konishi; H Saji
Journal:  Ann Nucl Med       Date:  2001-02       Impact factor: 2.668

2.  Dexamethasone treatment and plasma glucose levels: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas.

Authors:  U Roelcke; R G Blasberg; K von Ammon; S Hofer; P Vontobel; R P Maguire; E W Radü; R Herrmann; K L Leenders
Journal:  J Nucl Med       Date:  1998-05       Impact factor: 10.057

3.  Hydrocortisne resistance of graft vs host activity in mouse thymus, spleen and bone marrow.

Authors:  J J Cohen; M Fschbach; H N Claman
Journal:  J Immunol       Date:  1970-11       Impact factor: 5.422

4.  Corticosteroids and lymphoid cells.

Authors:  H N Claman
Journal:  N Engl J Med       Date:  1972-08-24       Impact factor: 91.245

5.  Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool.

Authors:  G Di Chiro
Journal:  Invest Radiol       Date:  1987-05       Impact factor: 6.016

6.  Effects of methylprednisolone on peritumoral brain edema. A quantitative autoradiographic study.

Authors:  K Yamada; Y Ushio; T Hayakawa; N Arita; N Yamada; H Mogami
Journal:  J Neurosurg       Date:  1983-10       Impact factor: 5.115

7.  Effects of dexamethasone on tumor-induced brain edema and its distribution in the brain of monkeys.

Authors:  K Yamada; A M Bremer; C R West
Journal:  J Neurosurg       Date:  1979-03       Impact factor: 5.115

8.  Growth inhibition by glucocorticoids in RPMI 3460 melanoma cells.

Authors:  D Horn; R L Buzard
Journal:  Cancer Res       Date:  1981-08       Impact factor: 12.701

9.  In vitro growth inhibition of human malignant melanoma cells by glucocorticoids.

Authors:  D M DiSorbo; B McNulty; L Nathanson
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

10.  A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection.

Authors:  P Som; H L Atkins; D Bandoypadhyay; J S Fowler; R R MacGregor; K Matsui; Z H Oster; D F Sacker; C Y Shiue; H Turner; C N Wan; A P Wolf; S V Zabinski
Journal:  J Nucl Med       Date:  1980-07       Impact factor: 10.057

View more
  8 in total

Review 1.  A review of the past, present, and future directions of neoplasia.

Authors:  Alnawaz Rehemtulla; Brian D Ross
Journal:  Neoplasia       Date:  2005-12       Impact factor: 5.715

2.  [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung.

Authors:  Marcelo Mamede; Tatsuya Higashi; Masanori Kitaichi; Koichi Ishizu; Takayoshi Ishimori; Yuji Nakamoto; Kazuhiro Yanagihara; Mio Li; Fumihiro Tanaka; Hiromi Wada; Toshiaki Manabe; Tsuneo Saga
Journal:  Neoplasia       Date:  2005-04       Impact factor: 5.715

3.  Visualization of a primary anti-tumor immune response by positron emission tomography.

Authors:  Chengyi J Shu; Shuling Guo; Young J Kim; Stephanie M Shelly; Amar Nijagal; Pritha Ray; Sanjiv S Gambhir; Caius G Radu; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-17       Impact factor: 11.205

4.  Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo.

Authors:  Richard Tavaré; Melissa N McCracken; Kirstin A Zettlitz; Scott M Knowles; Felix B Salazar; Tove Olafsen; Owen N Witte; Anna M Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-03       Impact factor: 11.205

5.  Evaluation of treatment-associated inflammatory response on diffusion-weighted magnetic resonance imaging and 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography imaging biomarkers.

Authors:  Craig J Galbán; Mahaveer S Bhojani; Kuei C Lee; Charles R Meyer; Marcian E Van Dort; Kyle K Kuszpit; Robert A Koeppe; Rajesh Ranga; Bradford A Moffat; Timothy D Johnson; Thomas L Chenevert; Alnawaz Rehemtulla; Brian D Ross
Journal:  Clin Cancer Res       Date:  2010-02-16       Impact factor: 12.531

6.  Hyperpolarized Carbon-13 MRI for Early Response Assessment of Neoadjuvant Chemotherapy in Breast Cancer Patients.

Authors:  Ramona Woitek; Mary A McLean; Stephan Ursprung; Oscar M Rueda; Raquel Manzano Garcia; Matthew J Locke; Lucian Beer; Gabrielle Baxter; Leonardo Rundo; Elena Provenzano; Joshua Kaggie; Andrew Patterson; Amy Frary; Johanna Field-Rayner; Vasiliki Papalouka; Justine Kane; Arnold J V Benjamin; Andrew B Gill; Andrew N Priest; David Y Lewis; Roslin Russell; Ashley Grimmer; Brian White; Beth Latimer-Bowman; Ilse Patterson; Amy Schiller; Bruno Carmo; Rhys Slough; Titus Lanz; James Wason; Rolf F Schulte; Suet-Feung Chin; Martin J Graves; Fiona J Gilbert; Jean E Abraham; Carlos Caldas; Kevin M Brindle; Evis Sala; Ferdia A Gallagher
Journal:  Cancer Res       Date:  2021-10-08       Impact factor: 13.312

Review 7.  Visualizing cancer and immune cell function with metabolic positron emission tomography.

Authors:  Rachel E Laing; Evan Nair-Gill; Owen N Witte; Caius G Radu
Journal:  Curr Opin Genet Dev       Date:  2010-02       Impact factor: 5.578

8.  Assessment of early changes in 3H-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expression.

Authors:  Songji Zhao; Yuji Kuge; Yan Zhao; Satoshi Takeuchi; Kenji Hirata; Toshiki Takei; Tohru Shiga; Hirotoshi Dosaka-Akita; Nagara Tamaki
Journal:  BMC Cancer       Date:  2013-11-06       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.